Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
50%(1 trials)

Phase Distribution

Phase 1
1
25%
Phase 2
3
75%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed250%
active_not_recruiting125%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

NCT06664814
active_not_recruitingphase_2

Multi-Center Study of ManNAc for GNE Myopathy

NCT04231266
completedphase_2

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

NCT02346461
completedphase_1

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

NCT01634750

Clinical Trials (4)

Showing 4 of 4 trials
NCT06664814Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

Recruiting
NCT04231266Phase 2

Multi-Center Study of ManNAc for GNE Myopathy

Active Not Recruiting
NCT02346461Phase 2

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Completed
NCT01634750Phase 1

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Completed

All 4 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
4